DNLI News and Press, Denali Therapeutics Inc. From 07/17/23

2023-07-17 00:45:27 ET Summary Denali Therapeutics reported Q1 2023 losses of $109.8 million, up from $65.2 million in Q1 2022, with reduced revenue from partnerships with Takeda and Biogen. The company's Phase 1/2 trial for DNL310, a treatment for Hunter syndrome, showed a signif...

2023-06-29 05:13:37 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Longevity efforts are forefront of the news cycle today, due in large part to recent coverage of tech billionaire Bryan Johnson’s unique strategy to delay aging . This has investors ...

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs PR Newswire Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively Th...

Interim results demonstrate average reduction of 64% (p <0.001) from baseline in serum NfL after 2 years of dosing with DNL310 in Phase 1/2 study FDA has recommended assessment of NfL, a marker of neuroaxonal damage, as a possible biomarker in MPS II Additional interim data from the ...

2023-06-05 10:26:34 ET Denali Therapeutics ( NASDAQ: DNLI ) announced Monday that the company and its partner Biogen ( BIIB ) have decided to discontinue a Phase 3 trial for Parkinson’s disease (PD) candidate BIIB122 (DNL151). The company said the decision follows a r...

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry PR Newswire The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefi...

2023-05-15 16:31:43 ET Shares of Denali Therapeutics (NASDAQ: DNLI) were up more than 14% Monday afternoon. The company reported first-quarter earnings a week ago, and three analysts recently maintained their buy ratings on the clinical-stage biotech company, which focuses on th...

2023-05-08 17:13:08 ET Denali Therapeutics press release ( NASDAQ: DNLI ): Q1 GAAP EPS of -$0.80 misses by $0.10 . Revenue of $35.14M (-16.6% Y/Y) beats by $5.26M . For further details see: Denali Therapeutics GAAP EPS of -$0.80 misses by $0.10, revenue o...

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal sto...

2023-04-17 06:52:08 ET Summary Denali Therapeutics is poised to revolutionize the industry with its proprietary Transport Vehicle (TV) technology, designed to effectively cross the blood-brain barrier. The company's robust and diversified therapeutic portfolio includes seven progr...